Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ: GH )

47.78 +0.18 (+0.38%)
Streaming Delayed Price Updated: 10:42 AM EST, Feb 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Guardant Health Announces Collaboration With AstraZeneca to Develop Companion Diagnostic to Identify Patients With ESR1-mutated Metastatic Breast Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer Patients
From Guardant Health, Inc.
Via Business Wire
Guardant Health Reports Third Quarter 2022 Financial Results
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Third Quarter 2022 Financial Results on November 3, 2022
From Guardant Health, Inc.
Via Business Wire
Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner
From Guardant Health, Inc.
Via Business Wire
Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients
From Guardant Health, Inc.
Via Business Wire
Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers
From Guardant Health, Inc.
Via Business Wire
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference
From Guardant Health, Inc.
Via Business Wire
Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health Reports Second Quarter 2022 Financial Results
From Guardant Health, Inc.
Via Business Wire
Guardant Health Receives Medicare Coverage for Guardant Reveal™ Test
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Second Quarter 2022 Financial Results on August 4, 2022
From Guardant Health, Inc.
Via Business Wire
Steve E. Krognes Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming June Investor Conferences
From Guardant Health, Inc.
Via Business Wire
First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d’Hebron Institute of Oncology
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Guardant Health, Inc.
Via Business Wire
Guardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-of-its Kind Prospective Study at Digestive Disease Week 2022
From Guardant Health, Inc.
Via Business Wire
Guardant Health Reports First Quarter 2022 Financial Results
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the BofA Securities 2022 Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report First Quarter Financial Results on May 5, 2022
From Guardant Health, Inc.
Via Business Wire
Guardant Health Presents New Data Showing Blood Test Highly Accurate in Detecting Multiple Cancers at the American Association for Cancer Research Annual Meeting
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Partnership with Epic to Streamline Access to Company’s Broad Portfolio of Cancer Tests
From Guardant Health, Inc.
Via Business Wire
Guardant Health Response to Frivolous and Retaliatory Lawsuit Filed by Illumina
From Guardant Health, Inc.
Via Business Wire
Guardant Health Receives Regulatory Approval for Guardant360® CDx in Japan
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.